Código QR (código de barras bidimensional)

Tofogliflozin attenuates liver steatosis and fibrosis in non-diabetic non-alcoholic steatohepatitis mice

Abstract Background Nonalcoholic fatty liver disease (NAFLD) is a leading cause of chronic liver disease with increasing global prevalence. Although diabetes is a major factor in NAFLD progression, up to 75% of the patients with NAFLD do not have diabetes. Tofogliflozin (Tofo), a sodium-glucose cotr...

Fuld beskrivelse

Na minha lista:
Principais autores: Yoshinori Ozono, Hiroshi Kawakami, Hiroshi Hatada, Naomi Uchiyama, Souichiro Ogawa, Keisuke Uchida, Hotaka Tamura, Yuri Komaki, Kenichi Nakamura, Hisayoshi Iwakiri, Satoru Hasuike, Kenji Nagata
Format: Artigo
Sprog:Inglês
Udgivet: BMC 2026-01-01
Serier:BMC Gastroenterology
Fag:
NAFLD
NASH
Tofogliflozin
Diabetes
CDAHFD
Online adgang:https://doi.org/10.1186/s12876-026-04610-1
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker